These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1296 related items for PubMed ID: 24332299

  • 1. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [Abstract] [Full Text] [Related]

  • 2. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.
    Vaccine; 2013 Dec 30; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [Abstract] [Full Text] [Related]

  • 3. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [Abstract] [Full Text] [Related]

  • 4. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [Abstract] [Full Text] [Related]

  • 5. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.
    Ginsberg GM.
    Vaccine; 2013 Nov 22; 31 Suppl 8():I46-52. PubMed ID: 24229719
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 7. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.
    Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H32-45. PubMed ID: 24332296
    [Abstract] [Full Text] [Related]

  • 8. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [Abstract] [Full Text] [Related]

  • 9. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
    Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjänen S.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H59-70. PubMed ID: 24332298
    [Abstract] [Full Text] [Related]

  • 10. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 11. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 12. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 13. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM, Genuino AJ, Santillan M, Praditsitthikorn N, Chantarastapornchit V, Teerawattananon Y, Alejandria M, Toral JA.
    BMC Public Health; 2015 Jul 30; 15():730. PubMed ID: 26223975
    [Abstract] [Full Text] [Related]

  • 14. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.
    BJOG; 2012 Jan 30; 119(2):177-86. PubMed ID: 21794070
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.
    Vaccine; 2015 May 07; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 17. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA, Lepetic A, Demarteau N.
    BMC Public Health; 2014 Nov 26; 14():1222. PubMed ID: 25424716
    [Abstract] [Full Text] [Related]

  • 18. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
    Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.
    Br J Cancer; 2008 Jul 22; 99(2):230-8. PubMed ID: 18612311
    [Abstract] [Full Text] [Related]

  • 19. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N.
    Vaccine; 2015 May 07; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.